Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (491-500 of 567) with videos related to

Pageof 57
Sort By:
Nature Communications|August 9, 2017
Corrigendum: Allelic variation contributes to bacterial host specificityMin Yue, Xiangan Han, Leon De Masi, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A McGregor, Rana R McKay, David A Braun, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaLucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology|November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database ConsortiumFabio A B Schutz, Wanling Xie, Frede Donskov, et al.
Pageof 57

Showing results (491-500 of 567) with videos related to

Sort By:
Pageof 57
Nature Communications|August 9, 2017
Corrigendum: Allelic variation contributes to bacterial host specificityMin Yue, Xiangan Han, Leon De Masi, et al.
Journal for Immunotherapy of Cancer|November 29, 2016
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinomaBrian I Rini, David F McDermott, Hans Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2019
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesBradley A McGregor, Rana R McKay, David A Braun, et al.
Journal for Immunotherapy of Cancer|September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanomaElizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyDaniel Y C Heng, Wanling Xie, Meredith M Regan, et al.
Cancer Immunology, Immunotherapy : CII|October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinomaAjjai Alva, Gregory A Daniels, Michael K K Wong, et al.
European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinomaLucia Carril-Ajuria, Pernelle Lavaud, Cecile Dalban, et al.
Oncology|August 25, 2010
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access programRonald M Bukowski, Walter M Stadler, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology|November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database ConsortiumFabio A B Schutz, Wanling Xie, Frede Donskov, et al.
Pageof 57